Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Mar 1.

Published in final edited form as: Lab Invest. 2010 May 10;90(9):1325–1338. doi: 10.1038/labinvest.2010.99

Resveratrol renders xenografted cholangiocarcinoma tumors more susceptible to 5-FU in vivo. Mz-ChA-1 cells were injected into the flank of athymic mice. After tumors were established, mice were treated with 20 mg/kg/day (ip) of resveratrol, 10 mg/kg/day of 5-FU or resveratrol and 5-FU in combination, three days per week for 38 days and tumor volume assessed (A). Tumor latency was assessed as the time taken for the tumor to grow to 150% of the original size (B). Data are expressed as average latency (days ± SEM) and the * denotes significance (p<0.05) from vehicle-treated tumors and the # denotes significance (p<0.05) from 5-FU treated tumors.

Resveratrol renders xenografted cholangiocarcinoma tumors more susceptible to 5-FU in vivo. Mz-ChA-1 cells were injected into the flank of athymic mice. After tumors were established, mice were treated with 20 mg/kg/day (ip) of resveratrol, 10 mg/kg/day of 5-FU or resveratrol and 5-FU in combination, three days per week for 38 days and tumor volume assessed (A). Tumor latency was assessed as the time taken for the tumor to grow to 150% of the original size (B). Data are expressed as average latency (days ± SEM) and the * denotes significance (p<0.05) from vehicle-treated tumors and the # denotes significance (p<0.05) from 5-FU treated tumors.